Torsdag 26 December | 23:13:11 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-04-24 N/A Årsstämma
2025-02-26 N/A Bokslutskommuniké 2024
2025-01-06 N/A Extra Bolagsstämma 2025
2024-08-30 - Kvartalsrapport 2024-Q2
2024-04-12 - X-dag ordinarie utdelning TRMED 0.00 NOK
2024-04-11 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-08-31 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning TRMED 0.00 NOK
2023-04-26 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-31 - Kvartalsrapport 2022-Q2
2022-04-29 - X-dag ordinarie utdelning TRMED 0.00 NOK
2022-04-28 - Årsstämma
2022-03-01 - Bokslutskommuniké 2021
2021-11-18 - 15-10 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-26 - Kvartalsrapport 2021-Q1
2021-04-28 - Årsstämma
2021-04-16 - X-dag ordinarie utdelning TRMED 0.00 NOK
2021-03-22 - Extra Bolagsstämma 2021
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-10-21 - Extra Bolagsstämma 2020
2020-08-27 - Kvartalsrapport 2020-Q2
2020-06-11 - X-dag ordinarie utdelning TRMED 0.00 NOK
2020-06-10 - Årsstämma
2020-05-26 - Kvartalsrapport 2020-Q1
2020-04-20 - X-dag ordinarie utdelning TRMED 0.00 NOK
2020-02-27 - Bokslutskommuniké 2019
2019-11-19 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-23 - Kvartalsrapport 2019-Q1
2019-04-26 - X-dag ordinarie utdelning TRMED 0.00 NOK
2019-04-25 - Årsstämma
2019-02-18 - Extra Bolagsstämma 2019
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-31 - X-dag ordinarie utdelning TRMED 0.00 NOK
2018-05-30 - Årsstämma
2018-05-30 - Kvartalsrapport 2018-Q1
2018-02-27 - Bokslutskommuniké 2017
2017-12-20 - Extra Bolagsstämma 2017
2017-11-22 - Kvartalsrapport 2017-Q3
2017-08-23 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning TRMED 0.00 NOK
2017-05-24 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-02-28 - Bokslutskommuniké 2016
2016-11-23 - Kvartalsrapport 2016-Q3
2016-10-12 - Extra Bolagsstämma 2016
2016-08-24 - Kvartalsrapport 2016-Q2
2016-05-31 - Kapitalmarknadsdag 2016
2016-05-20 - X-dag ordinarie utdelning TRMED 0.00 NOK
2016-05-19 - Årsstämma
2016-05-19 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015
2015-11-17 - Kapitalmarknadsdag 2015
2015-10-21 - Kvartalsrapport 2015-Q3
2015-08-26 - Kvartalsrapport 2015-Q2
2015-05-27 - Kvartalsrapport 2015-Q1
2015-03-09 - Årsstämma
2014-11-12 - Extra Bolagsstämma 2014

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Thor Medical är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo, Norge.
2022-03-23 08:46:34

Oslo, Norway, 23 March 2022

Reference is made to the stock exchange announcement made by Nordic Nanovector ASA's (OSE: NANOV) (the "Company") on 31 January 2019, regarding allocation of 259,000 PSUs to employees in accordance with the authorisation granted at the Company's annual general meeting held 30 May 2018 (the "2018 AGM"). Each vested PSU will give the holder the right to receive one share in the Company at an exercise price corresponding to the par value of the shares being NOK 0.20. The total program ended at 42,675 vested PSUs which were exercised on 22 March 2022.

Out of the 42,675 vested PSUs, 14,466 PSUs were exercised by primary insiders. Malene Brondberg, CFO exercised 7,233 PSUs and Jostein Dahle, CSO exercised 7,233 PSUs.

The exercise of PSUs will be settled by issuance of new shares against warrants issued by the Company pursuant to the resolution by the 2018 AGM.

Primary insider notifications pursuant to the Market Abuse Regulation article 19 are attached.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (MEDiSTRAVA Consulting)

Tel: +44 207 638 9571

Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of CD37-targeted therapies for haematological cancers and immune diseases. Nordic Nanovector's lead clinical-stage candidate is Betalutin[®], a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 27 billion by 2029. Nordic Nanovector retains global marketing rights to Betalutin[®] and intends to actively participate in the commercialisation of Betalutin[®] in the US and other major markets.

Further information can be found at www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrava.com%7Cbd8fdb7f05284d3963a108d9d20ae447%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7C0%7C637771766496096573%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=xp8WBxqCMdEa4qM%2FjJAyw9bnfalGpQqswXzSzRJqqWo%3D&reserved=0).

This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation, article 19, and the Norwegian Securities Trading Act, section 5 -12.